Novo Nordisk, food and drug administration
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...
Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...
Senators grilled the top executive of Novo Nordisk over why the Danish company charges Americans far more for the blockbuster weight-loss drug Wegovy and diabetes drug Ozempic than it does ...
The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter ...
Novo Nordisk has a price fix solution for uninsured patients with diabetes, but not for HSA holders or people with normal ...
The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...
The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam.Most Read from ...